SG11201504897YA - Anti her2 antibody formulation - Google Patents

Anti her2 antibody formulation

Info

Publication number
SG11201504897YA
SG11201504897YA SG11201504897YA SG11201504897YA SG11201504897YA SG 11201504897Y A SG11201504897Y A SG 11201504897YA SG 11201504897Y A SG11201504897Y A SG 11201504897YA SG 11201504897Y A SG11201504897Y A SG 11201504897YA SG 11201504897Y A SG11201504897Y A SG 11201504897YA
Authority
SG
Singapore
Prior art keywords
her2 antibody
antibody formulation
anti her2
formulation
her2
Prior art date
Application number
SG11201504897YA
Other languages
English (en)
Inventor
Jonathan André Albanese
Roberto Pier-Lorenzo Giovannini
Kevin Niall O'mahony
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of SG11201504897YA publication Critical patent/SG11201504897YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG11201504897YA 2012-12-21 2013-12-18 Anti her2 antibody formulation SG11201504897YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745293P 2012-12-21 2012-12-21
PCT/EP2013/077166 WO2014096051A1 (fr) 2012-12-21 2013-12-18 Préparation d'anticorps anti-her2

Publications (1)

Publication Number Publication Date
SG11201504897YA true SG11201504897YA (en) 2015-07-30

Family

ID=49779926

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504897YA SG11201504897YA (en) 2012-12-21 2013-12-18 Anti her2 antibody formulation

Country Status (16)

Country Link
US (2) US20150343058A1 (fr)
EP (1) EP2934582B1 (fr)
JP (2) JP6400595B2 (fr)
AU (1) AU2013360812B2 (fr)
BR (1) BR112015014853A2 (fr)
CA (1) CA2895869C (fr)
DK (1) DK2934582T3 (fr)
EA (1) EA201391729A1 (fr)
ES (1) ES2773103T3 (fr)
HK (1) HK1215796A1 (fr)
IL (1) IL239509A0 (fr)
MX (2) MX367748B (fr)
PL (1) PL2934582T3 (fr)
SG (1) SG11201504897YA (fr)
WO (1) WO2014096051A1 (fr)
ZA (1) ZA201504564B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
AR119293A1 (es) 2019-06-28 2021-12-09 Genentech Inc Composición y métodos para estabilizar formulaciones líquidas de proteínas
EP3999537A1 (fr) * 2019-07-19 2022-05-25 Ichnos Sciences SA Formulation d'anticorps lyophilisée
CN115175737A (zh) 2020-02-28 2022-10-11 瑞泽恩制药公司 结合her2的双特异性抗原结合分子及其使用方法
CN114762727A (zh) * 2021-01-15 2022-07-19 海正生物制药有限公司 一种稳定的帕妥珠单抗的药物组合物
WO2023140807A1 (fr) * 2022-01-19 2023-07-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques de trastuzumab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504605A (ja) * 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DK2275119T3 (da) * 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
DE69810481T2 (de) * 1997-06-13 2003-09-25 Genentech Inc Stabilisierte antikörperformulierung
US7452539B2 (en) * 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
US20060182740A1 (en) * 2002-06-21 2006-08-17 Biogen Idec, Inc. Buffered formulations for concentrating antibodies and methods of use thereof
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2390267B1 (fr) * 2005-06-07 2013-06-05 ESBATech - a Novartis Company LLC Anticorps stables et solubles inhibant le TNF (alpha)
KR20080031684A (ko) * 2005-06-14 2008-04-10 암젠 인코포레이티드 자가 - 완충성 단백질 제형
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof

Also Published As

Publication number Publication date
WO2014096051A1 (fr) 2014-06-26
PL2934582T3 (pl) 2020-08-10
CA2895869C (fr) 2020-09-22
US20200061190A1 (en) 2020-02-27
DK2934582T3 (da) 2020-02-24
ZA201504564B (en) 2016-11-30
AU2013360812A1 (en) 2015-07-09
EP2934582A1 (fr) 2015-10-28
CA2895869A1 (fr) 2014-06-26
MX2019010479A (es) 2019-10-15
EA201391729A1 (ru) 2014-09-30
US20150343058A1 (en) 2015-12-03
AU2013360812B2 (en) 2018-11-08
WO2014096051A9 (fr) 2014-10-02
HK1215796A1 (zh) 2016-09-15
MX2015008194A (es) 2016-02-05
JP2018199720A (ja) 2018-12-20
IL239509A0 (en) 2015-08-31
JP2016508973A (ja) 2016-03-24
JP6400595B2 (ja) 2018-10-03
MX367748B (es) 2019-09-04
ES2773103T3 (es) 2020-07-09
EP2934582B1 (fr) 2019-11-27
BR112015014853A2 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
HK1203146A1 (en) Antibody formulation
IL235807A0 (en) Immunoprecipitates containing anti–cd79b antibodies
IL235989A0 (en) Immunoprecipitates containing anti–cd79b antibodies
RS59221B1 (sr) Formulacije antitela
AP2014008102A0 (en) Anti-FcRn antibodies
EP2841082A4 (fr) Anticorps régulés par les protéases
EP2930240A4 (fr) Anticorps anti-folr1
EP2875051A4 (fr) Anticorps anti-siglec-15
ZA201407316B (en) Anti-fgfr2 antibody
HK1215796A1 (zh) 抗體製劑
EP2826790A4 (fr) Anticorps anti-gremlin 1
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
HK1199844A1 (zh) 抗體配方
GB201220242D0 (en) Antibody
EP2848633A4 (fr) Anticorps anti-cxadr
EP2811018A4 (fr) ANTI-CORPS ANTI-sAPPß